Study of CM310 in Subjects With Seasonal Allergic Rhinitis

A Multicenter, Single Arm Phase II Clinical Study Evaluating the Efficacy of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Seasonal Allergic Rhinitis

This study is a multicenter, single arm phase II clinical study mainly evaluating the efficacy of CM310 in patients with seasonal allergic rhinitis.

Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.

Inclusion Criteria:

• Male or female aged 18-65.
• Understand the study and sign the Informed Consent Form voluntarily.
• Take effective contraception measures throughout the study period.

Exclusion Criteria:

• Used other investigational drugs.
• Allergies to drugs with IL-4Rα monoclonal antibody or drug components of CM310.
• Plan to participate in other studies during this clinical trial.
• With malignant or benign tumors of the nasal cavity.
• Other reasons the researcher believes that the subject is not suitable to participate in this study.